CDMOs race to add capacity as cell and gene therapy demand outpaces supply
Dr. Dereck Mush, MD, MBA
What they do
The company provides a cloud-native platform for sequence design, data management, and machine learning modeling for gene therapies. Customers include academic research laboratories and commercial biotechnology developers.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- Bioinformatics platform
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Dallas, United States
- Region
- North America
- Founded
- 2022
- Total funding
- $30M raised
Notable investors: JAZZ Venture Partners, Builders VC.
Also in Biotech & Pharma
Related on The Signal
Dr. Dereck Mush, MD, MBA
Closing the Assay Loop: Inside Anthropic's $400M Wet Lab Pivot
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
The biotech IPO window is reopening, cautiously, and the terms have changed
Dr. Dereck Mush, MD, MBA